Skip to main content

Advertisement

SpringerLink
Log in

Schmerztherapie mit antipyretischen Analgetika

Pain therapy with antipyretic analgesics

  • Leitthema
  • Published:
Der Orthopäde Aims and scope Submit manuscript

Zusammenfassung

Die Pharmakotherapie muskuloskelettaler Schmerzen besitzt in den westlichen Industrieländern einen hohen Stellenwert. Die vorliegende Übersicht konzentriert sich auf den Einsatz saurer (nicht-steroidale Antiphlogistika) und nicht-saurer [Paracetamol, selektive Zyklooxygenase- (COX-)2-Hemmer] antipyretischer Analgetika in der Therapie muskuloskelettaler Schmerzzustände. Schwerpunkt der Darstellung sind die unterschiedlichen kinetischen Eigenschaften und unerwünschten Wirkungen dieser Substanzen.

Abstract

The pharmacotherapy of musculoskeletal pain remains of high importance in Western countries. The present review concentrates on the use of acidic (nonsteroidal anti-inflammatory drugs) and nonacidic (paracetamol, selective cyclooxygenase-2 inhibitors) antipyretic analgesics in the therapy of musculoskeletal pain disorders with particular emphasis on the diverse pharmacokinetic properties and unwanted side effects of these substances.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Ahmadi S, Lippross S, Neuhuber WL, Zeilhofer HU (2002) PGE2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons. Nat Neurosci 5: 34–40

    Article  PubMed  Google Scholar 

  2. Akopian AN, Sivilotti L, Wood JN (1996) A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature 379: 257–262

    Article  PubMed  Google Scholar 

  3. Baba H, Kohno T, Moore KA, Woolf CJ (2001) Direct activation of rat spinal dorsal horn neurons by prostaglandin E2. J Neurosci 21: 1750–1756

    PubMed  Google Scholar 

  4. Beiche F, Scheuerer S, Brune K et al. (1996) Upregulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation. FEBS Lett 390: 165–169

    Article  PubMed  Google Scholar 

  5. Bombardier C, Laine L, Reicin A et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520–1528

    PubMed  Google Scholar 

  6. Boutaud O, Aronoff DM, Richardson JH et al. (2002) Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci USA 99: 7130–7135

    Article  PubMed  Google Scholar 

  7. Brandt K (2003) Paracetamol in the treatment of osteoarthritis pain. Drugs 63(2): 23–41

    Article  Google Scholar 

  8. Bresalier RS, Sandler RS, Quan H et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352: 1092–1102

    Article  PubMed  Google Scholar 

  9. Brune K, Hinz B (2004) Selective cyclooxygenase-2 inhibitors: similarities and differences. Scand J Rheumatol 33: 1–6

    PubMed  Google Scholar 

  10. Brune K, Lanz R (1985) Pharmacokinetics of non-steroidal anti-inflammatory drugs. In: Bonta IL, Bray MA, Parnham MJ (eds) Handbook of inflammation, Vol 5, The Pharmacology of Inflammation. Elsevier, Amsterdam, pp 413–449

  11. Cannon CP, Curtis SP, FritzGerald GA et al. for the MEDAL Steering Commitee (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) programme: a randomided comparison. Lancet, published anline Nov 13, 2006

  12. Catella-Lawson F, McAdam B, Morrison BW et al. (1999) Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 289: 735–741

    PubMed  Google Scholar 

  13. Catella-Lawson F, Reilly MP, Kapoor SC et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809–1817

    Article  PubMed  Google Scholar 

  14. Caterina MJ, Leffler A, Malmberg AB et al. (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288: 306–313

    Article  PubMed  Google Scholar 

  15. Chandrasekharan NV, Dai H, Roos KL et al. (2002) COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 99: 13926–13931

    Article  PubMed  Google Scholar 

  16. Cheng Y, Austin SC, Rocca B et al. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539–541

    Article  PubMed  MathSciNet  Google Scholar 

  17. Davis JB, Gray J, Gunthorpe MJ et al. (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 11(405): 183–187

    Article  Google Scholar 

  18. Dinchuk JE, Liu RQ, Trzaskos JM (2003) COX-3: in the wrong frame in mind. Immunol Lett 86: 121

    Article  PubMed  Google Scholar 

  19. EMEA (2005) Press release: European Medicines Agency concludes action on COX-2 inhibitors. London, 27 June 2005. Doc. Ref. EMEA/207766/2005

    Google Scholar 

  20. EMEA (2005) Press release: European Medicines Agency update on non-selective NSAIDs. London, 17 October 2005. Doc. Ref. EMEA/298964/2005

    Google Scholar 

  21. EMEA (2005) Key elements fort he summaries of product characteristics of non-selective NSAIDs adopted by the CHMP during its meeting in October 2005. Doc. Ref EMEA/CHMP/343456/2005

  22. EMEA (2006) European Medicines Agency review concludes positive benefit-risk balance for non-selective NSAIDs. Doc. Ref EMEA/413136/2006

  23. Empfehlungen zur Therapie von Fettstoffwechselstörungen (1999) Arzneiverordnung in der Praxis. Sonderheft Therapieempfehlungen der Arzneimittelkommission der Deutschen Ärzteschaft, 2. Aufl. AkdÄ, Berlin

  24. Farkouh ME, Kirshner H, Harrington RA et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675–684

    Article  PubMed  Google Scholar 

  25. FDA (2005) FDA News: FDA announces series of changes to the class of marketed non-steroidal anti-inflammatory drugs (NSAID). http://www.fda.gov/bbs/topics/news/2005/NEW01171.html

    Google Scholar 

  26. FDA (2006) FDA Science Paper: Concomitant use of ibuprofen and aspirin: potential for attenuation of the antiplatelet effect of aspirin. 9/8/2006 http://www.fda.gov/cder/drug/infopage/ibuprofen/default.htm

  27. Forman JP, Stampfer MJ, Curhan GC (2005) Non-narcotic analgesic dose and risk of incident hypertension in US women. Hypertension 46: 500–507

    Article  PubMed  Google Scholar 

  28. Gavett SH, Madison SL, Chulada PC et al. (1999) Allergic lung responses are increased in prostaglandin H synthase-deficient mice. J Clin Invest 104: 721–732

    PubMed  Google Scholar 

  29. Geba GP, Weaver AL, Polis AB et al. (VACT) Group (2002) Efficacy of rofecoxib, celecoxib, and acetaminophen in osteoarthritis of the knee: a randomized trial. JAMA 287: 64–71

    Article  PubMed  Google Scholar 

  30. Giannitsis E (2005) Rationale for testing the cardiovascular risk for patients with COX-2 inhibitors on the basis of biomarker NT-proBNP. Clin Lab 51: 63–83

    PubMed  Google Scholar 

  31. Gyllfors P, Bochenek G, Overholt J et al. (2003) Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib. J Allergy Clin Immunol 111: 1116–1121

    Article  PubMed  Google Scholar 

  32. Hansson L, Zanchetti A, Carruthers SG et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 1755–1762

    Article  PubMed  Google Scholar 

  33. Harvey RJ, Depner UB, Wassle H et al. (2004) GlyR α3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science 304: 884–887

    Article  PubMed  Google Scholar 

  34. Hernandes-Diaz S, Varas-Lorenzo C, Garcia Rodriguez LA (2006) Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction. Basic Clin Pharmacol Toxicol 98: 266–274

    Article  PubMed  Google Scholar 

  35. Hinz B, Brune K (2002) Cyclooxygenase-2 – Ten years later. J Pharmacol Exp Ther 300: 367–375

    Article  PubMed  Google Scholar 

  36. Hinz B, Brune K (2004) Non-steroidal anti-inflammatory drugs – old and new. In: Isenberg DH, Maddison PJ, Woo P, Glass D, Breedveld FC (eds) Oxford textbook of rheumatology, 3rd edn. Oxford University Press, Oxford, pp 442–450

  37. Hinz B, Dormann H, Brune K (2006) More pronounced inhibition of cyclooxygenase-2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 54: 282–291

    Article  PubMed  Google Scholar 

  38. Hippisley-Cox J, Coupland C (2005) Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 330: 1366

    Article  PubMed  Google Scholar 

  39. Kearney PM, Baigent C, Godwin J et al. (2006) Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomided trials. BMJ 332: 1302–1308

    Article  PubMed  Google Scholar 

  40. Muth-Selbach US, Tegeder I, Brune K, Geisslinger G (1999) Acetaminophen inhibits spinal prostaglandin E2 release after peripheral noxious stimulation. Anesthesiology 91: 231–239

    Article  PubMed  Google Scholar 

  41. NIH (2004) NIH News. Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer’s disease prevention trial. http://www.nih.gov/news/pr/dec2004/od-20.htm

  42. Nussmeier NA, Whelton AA, Brown MT et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081–1091

    Article  PubMed  Google Scholar 

  43. Ott E, Nussmeier NA, Duke PC et al. (2003) Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg 125: 1481–1492

    Article  PubMed  Google Scholar 

  44. Pincus T, Koch G, Lei H et al. (2004) Patient preference for placebo, Acetaminophen (paracetamol) or Celecoxib efficacy studies (PACES): two randomised, double blind, placebo controlled, crossover clinical trials in patients with knee or hip osteoarthritis. Ann Rheum Dis 63: 931–939

    Article  PubMed  Google Scholar 

  45. Rabausch K, Bretschneider E, Sarbia M et al. (2005) Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res 96: 1–6

    Article  Google Scholar 

  46. Reinold H, Ahmadi S, Depner UB et al. (2005) Spinal inflammatory hyperalgesia is mediated by prostaglandin E receptors of the EP2 subtype. J Clin Invest 115: 673–679

    Article  PubMed  Google Scholar 

  47. Sanchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A (2005) Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 95: 154–158

    PubMed  Google Scholar 

  48. Schnitzer TJ (2002) Update of ACR guidelines for osteoarthritis: role of the coxibs. J Pain Symptom Manage 23 [4 Suppl]: 24–30

    Article  Google Scholar 

  49. Schnitzer TJ, Burmester GR, Mysler E et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 364: 665–674

    Article  PubMed  Google Scholar 

  50. Schwab JM, Beiter T, Linder JU et al. (2003) COX-3 – a virtual pain target in humans? FASEB J 17: 2174–2175

    Article  PubMed  Google Scholar 

  51. Schwartz JI, Vandormael K, Malice MP et al. (2002) Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 72: 50–61

    Article  PubMed  Google Scholar 

  52. Seeff LB, Cuccherini BA, Zimmerman HJ et al. (1986) Paracetamol hepatotoxicity in alcoholics. Ann Intern Med 104: 399–404

    PubMed  Google Scholar 

  53. Silverstein FE, Faich G, Goldstein JL et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. J Am Med Assoc 284: 1247–1255

    Article  Google Scholar 

  54. Singh G, Miller JD, Huse DM et al. (2003) Consequences of increased systolic blood pressure in patients with osteoarthritis and rheumatoid arthritis. J Rheumatol 30: 714–719

    PubMed  Google Scholar 

  55. Singh G, Mithal A, Triadafilopoulos G (2005) Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient, not with the drug class. Annual European Congress of Rheumatology, Vienna, 8–11 June 2005; Abstract OP0091

  56. Solomon SD, McMurray JJ, Pfeffer MA et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071–1080

    Article  PubMed  Google Scholar 

  57. Szczeklik A, Nizankowska E, Bochenek G et al. (2001) Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 31: 219–225

    Article  PubMed  Google Scholar 

  58. Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature New Biol 231: 232–235

    PubMed  Google Scholar 

  59. Zhang W, Jones A, Doherty M (2004) Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 63: 901–907

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

K. B. hat sämtliche auf dem Gebiet der Analgetika/Antirheumatika forschenden Firmen beraten.

Trotz des möglichen Interessenkonflikts ist der Beitrag unabhängig und produktneutral.

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Friedrich-Alexander-Universität Erlangen-Nürnberg, Fahrstraße 17, 91054, Erlangen, Deutschland

    B. Hinz & K. Brune

Authors
  1. B. Hinz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Brune
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to B. Hinz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hinz, B., Brune, K. Schmerztherapie mit antipyretischen Analgetika. Orthopäde 36, 23–31 (2007). https://doi.org/10.1007/s00132-006-1024-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00132-006-1024-9

Schlüsselwörter

Keywords

Search

Navigation